The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.

The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.

American Society of Nuclear Cardiology (ASNC) 2023 President Mouaz H. Al-Mallah, MD, said the subspecialty needs to up its game with new technology.

Munir Ghesani, MD, president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and system chief of nuclear medicine at Mount Sinai Health, explains PSMA-PET has seen rapid adoption because it can significantly improve prostate cancer detection and treatment.